<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850496</url>
  </required_header>
  <id_info>
    <org_study_id>15HH2472</org_study_id>
    <secondary_id>171441</secondary_id>
    <secondary_id>15/LO/0620</secondary_id>
    <nct_id>NCT03850496</nct_id>
  </id_info>
  <brief_title>DESIVI: Dosing of Electrical Stimulation in Venous Insufficiency</brief_title>
  <acronym>DESIVI</acronym>
  <official_title>Dosing of Electrical Stimulation in Venous Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actegy Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to describe the difference in varicose vein outcomes found from using
      a neuromuscular electrical stimulation device for different amounts of time - Group A
      (control - no device), Group B (device for 30 mins per day) and Group C (device for 60 mins
      per day). The groups are assessed after 6 weeks of intervention.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2015</start_date>
  <completion_date type="Actual">October 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Specific Quality of Life Measure - Aberdeen Varicose Vein Questionnaire</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment using the Aberdeen Varicose Vein Questionnaire disease specific questionnaire on quality of life. Assessed at baseline and at 6 weeks. Scored from 0-100. 100 worst 0 best.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Venous Flow Parameters - TAMV</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of change in venous flow utilising Time Averaged Mean Velocity (TAMV) (measured in cm/s), assessed as percentage change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Flow Parameters - PV</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of change in venous flow utilising Peak Velocity (PV) (measured in cm/s), assessed as percentage change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Flow Parameters - VF</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of change in venous flow utilising Volume Flow (VF) (measured in cc/min), assessed as percentage change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculatory Blood Flow</measure>
    <time_frame>6 weeks.</time_frame>
    <description>Microcirculatory blood flow measure utilising flux arbitrary units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb Volume</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in limb volume assessed in ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Clinical Severity</measure>
    <time_frame>6 weeks.</time_frame>
    <description>Clinical severity of venous disease as measured by the venous clinical severity score (VCSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Compliance</measure>
    <time_frame>6 weeks.</time_frame>
    <description>Compliance with device usage assessed with a patient completed diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic Quality of Life - EQ-5D</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quality of life as assessed by the EuroQol EQ-5D generic quality of life questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic Quality of Life - SF-12</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quality of life as assessed by the Short Form 12 (SF-12) generic quality of life tool. Assessed at baseline and 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic Quality of Life - EQ-VAS</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quality of life as assessed by the EuroQol Visual Analogue Scale (0-100) for generic Quality of life - EQ-VAS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Varicose Veins</condition>
  <condition>Venous Stasis</condition>
  <condition>Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No device utilised for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revitive IX Neuromuscular Stimulation Device</intervention_name>
    <description>Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with chronic venous insufficiency who have the following are eligible for the
        study:

          -  Able to understand the study and provide meaningful written informed consent for the
             study.

          -  Willing, able, and committed to participate in the procedures for the full length of
             the study.

          -  All ethnic groups, male or female above the age of 18 years.

          -  Diagnosis of chronic venous insufficiency (C3-C5 CEAP Classification)

          -  Blood pressure currently under moderate control (&lt; 160/100mmHg)

          -  No current foot ulceration

        Exclusion Criteria:

        Patients meeting any of the following criteria are to be excluded:

          -  Has an unstable condition (eg, psychiatric disorder, a recent history of substance
             abuse) that would affect compliance with protocol

          -  Pregnant

          -  Has a cardiac pacemaker, AICD or other implanted electrical device

          -  Has an Existing DVT.

          -  Has recent lower limb injury or lower back pain

          -  Has current foot ulceration or other skin ulcers

          -  Has any disorder that, in the opinion of the Investigator, might interfere with the
             conduct of the study.

          -  Has an ABPI &lt; 0.8
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raveena Ravikumar, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <results_first_submitted>June 10, 2019</results_first_submitted>
  <results_first_submitted_qc>September 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Available on request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Post publication.</ipd_time_frame>
    <ipd_access_criteria>On direct communication with researchers.</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>No device utilised for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
        </group>
        <group group_id="P3">
          <title>Group C</title>
          <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>No device utilised for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="5"/>
                    <measurement group_id="B2" value="59" spread="5"/>
                    <measurement group_id="B3" value="63" spread="5"/>
                    <measurement group_id="B4" value="60" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="25"/>
                    <count group_id="B4" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Specific Quality of Life Measure - Aberdeen Varicose Vein Questionnaire</title>
        <description>Assessment using the Aberdeen Varicose Vein Questionnaire disease specific questionnaire on quality of life. Assessed at baseline and at 6 weeks. Scored from 0-100. 100 worst 0 best.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>No device utilised for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
          </group>
          <group group_id="O3">
            <title>Group C</title>
            <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Specific Quality of Life Measure - Aberdeen Varicose Vein Questionnaire</title>
          <description>Assessment using the Aberdeen Varicose Vein Questionnaire disease specific questionnaire on quality of life. Assessed at baseline and at 6 weeks. Scored from 0-100. 100 worst 0 best.</description>
          <units>Scores on a scale (0-100)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.62" lower_limit="10.13" upper_limit="26.83"/>
                    <measurement group_id="O2" value="21.07" lower_limit="16.34" upper_limit="29.47"/>
                    <measurement group_id="O3" value="21.30" lower_limit="11.91" upper_limit="31.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.72" lower_limit="11.30" upper_limit="25.38"/>
                    <measurement group_id="O2" value="18.86" lower_limit="14.99" upper_limit="28.52"/>
                    <measurement group_id="O3" value="15.01" lower_limit="11.04" upper_limit="21.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Flow Parameters - TAMV</title>
        <description>Assessment of change in venous flow utilising Time Averaged Mean Velocity (TAMV) (measured in cm/s), assessed as percentage change from baseline.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Flow Parameters - PV</title>
        <description>Assessment of change in venous flow utilising Peak Velocity (PV) (measured in cm/s), assessed as percentage change from baseline.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Flow Parameters - VF</title>
        <description>Assessment of change in venous flow utilising Volume Flow (VF) (measured in cc/min), assessed as percentage change from baseline.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microcirculatory Blood Flow</title>
        <description>Microcirculatory blood flow measure utilising flux arbitrary units.</description>
        <time_frame>6 weeks.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Limb Volume</title>
        <description>Change in limb volume assessed in ml.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Clinical Severity</title>
        <description>Clinical severity of venous disease as measured by the venous clinical severity score (VCSS).</description>
        <time_frame>6 weeks.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Compliance</title>
        <description>Compliance with device usage assessed with a patient completed diary.</description>
        <time_frame>6 weeks.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Generic Quality of Life - EQ-5D</title>
        <description>Quality of life as assessed by the EuroQol EQ-5D generic quality of life questionnaire.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Generic Quality of Life - SF-12</title>
        <description>Quality of life as assessed by the Short Form 12 (SF-12) generic quality of life tool. Assessed at baseline and 6 weeks.</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Generic Quality of Life - EQ-VAS</title>
        <description>Quality of life as assessed by the EuroQol Visual Analogue Scale (0-100) for generic Quality of life - EQ-VAS</description>
        <time_frame>6 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>No device utilised for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
Revitive IX Neuromuscular Stimulation Device: Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Tristan Lane, Clinical Lecturer</name_or_title>
      <organization>Imperial College London</organization>
      <phone>02033117317</phone>
      <email>tristan.lane@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

